- 期刊
評論：台灣藥品給付協議實施特性分析
Commentary: characteristics of the implementation of managed entry agreements for drug reimbursement in Taiwan
參考文獻
Guarga L, Gasol M, Reyes A, et al. Implementing risk-sharing arrangements for innovative medicines: the experience in Catalonia (Spain). Value Health 2021;25:803-9. doi:10.1016/j.jval.2021.10.010
Dabbous M, Chachoua L, Caban A, Toumi M. Managed entry agreements: policy analysis from the european perspective. Value Health 2020;23:425-33. doi:10.1016/j.jval.2019.12.008
Buyukkaramikli NC, Wigfield P, Hoang MT. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England. Eur J Health Econ 2021;22:51-73. doi:10.1007/s10198-020-01228-2
Robinson MF, Mihalopoulos C, Merlin T, Roughead E. Characteristics of managed entry agreements in Australia. Int J Technol Assess Health Care 2018;34:46-55. doi:10.1017/S0266462317001106
Wenzl M, Chapman S. Performance-Based Managed Entry Agreements for New Medicines in OECD Countries and EU Member States: How They Work and Possible Improvements Going Forward. OECD Health Working Papers, No. 115. Paris: OECD Publishing, 2019. doi:10.1787/18152015
延伸閱讀
- 高雅芝（2022）。臺灣藥品給付「其他協議」實施特性分析〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU202201423
- 林婉蓉（2015）。論台灣與大陸生物藥品上市之安全性與品質管控規範及其比較研究−以基因工程製品為例〔碩士論文，國立清華大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0016-0508201514083946
- 周稚傑、葉明功、游翁斌、白璐（1999）。用藥趨勢分析：以醫藥分業實施前後台北縣市健保特約藥局接獲之釋出處方箋為例。Journal of Medical Sciences，20(3)，142-151。https://www.airitilibrary.com/Article/Detail?DocID=10114564-199912-201305270006-201305270006-142-151
- 黃薏秦（2018）。台灣新藥臨床試驗計畫審查流程及執行之探討與建議〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU201801868
- 蔡田木、謝文彥、林安倫、連鴻榮（2013）。An Assessment of the Effects of Drug Prevention and Therapeutic Treatments in Taiwan。矯政期刊，2(1)，25-74。https://doi.org/10.6905/JC.201301_2(1).0002